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 The deubiquitylase (DUB) family of enzymes maintains the dynamic state of the cellular 
ubiquitome by releasing ubiquitin from proteins. Accordingly, DUBs occupy key roles in almost all 
aspects of cell behaviour. Many DUBs show selectivity for particular linkage-types or positions 
within ubiquitin chains. Others show chain-type promiscuity, but select a distinct palette of 
protein substrates via interactions, established through binding modules outside the catalytic 
domain. The ubiquitin chain cleavage mode or chain linkage specificity has been related directly 
to biological functions. Examples include proteasomal ubiquitin recycling, DNA repair pathways 
and innate immune signaling. DUB cleavage specificity is also being harnessed for analysis of 
ubiquitin chain architecture. The recent development of highly specific DUB inhibitors heralds 
their emergence as a new class of therapeutic targets, linked to numerous disease states. 
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Introduction 
 Conjugation of the 76 amino acid polypeptide ubiquitin to substrate proteins is a reversible 
post-translational modification, involved in the regulation of most cellular processes. The ubiquitin 
system may be considered as the complement of proteins that convert free ubiquitin molecules to 
a complex code written upon 1000s of different substrate proteins 1-4. The net ubiquitylation 
status of the cell reflects the combined activities of several hundred ubiquitin conjugating 
enzymes (E1, E2 and E3s), counterbalanced by 99 currently identified deubiquitylases (or 
deubiquitinases, hereafter DUBs). The ubiquitin system has two main outputs: control of protein 
turnover by providing proteasomal and lysosomal targeting signals and governance of cell 
signaling networks by regulation of protein interactions and activities, akin to phosphorylation. 
Thus, the balance between ubiquitylation and deubiquitylation is tightly coupled to the regulation 
of protein levels and activity. DUBs also maintain cellular ubiquitin levels by processing newly 
synthesised ubiquitin molecules and reclaiming ubiquitin from proteins destined for degradation 
(Figure 1). The DUBs are currently drawn from 7 evolutionarily conserved families, two of which 
(MINDY and ZUP1) have been discovered only recently (Figure 2). 
 Ubiquitylation most commonly occurs at lysine residues of substrate proteins. Importantly 
ubiquitin’s seven internal lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63) 
allow for the generation of isopeptide linked ubiquitin chains of diverse architecture and length. 
Ubiquitin derives from 4 genes that code for linear fusion proteins incorporating one or more 
ubiquitin molecules, from which free ubiquitin is generated by DUB cleavage of the peptide bond 
5.  Linear or Met1-linked ubiquitin chains can also be assembled enzymatically from single 
ubiquitin moieties, through a unique E3 ligase complex known as the linear Ub chain assembly 
complex (LUBAC) 6. Further complexity is provided by post-translational modification of ubiquitin 
(e.g. phosphorylation, acetylation) and by linking to other ubiquitin-like molecules (e.g. SUMO, 
NEDD8, ISG15). These complex patterns constitute a “ubiquitin code”, which is read by hundreds 
of proteins that incorporate ubiquitin binding domains 1,7. 
 In a typical mammalian cell, more than half of total ubiquitin is represented by single 
ubiquitin molecules conjugated to lysine residues in the substrate (mono-ubiquitylation) 2,8. A 
further 10-20% of ubiquitin is incorporated into chains, for which the representation of each 
linkage type varies between cell types and cell states 2,8. Accordingly, DUBs handle ubiquitin 
modifications in two fundamentally distinct manners. Many are directed towards specific protein 
substrates via protein interaction domains distinct from the catalytic domain (catalogued in 
previous reviews 9,10). Other DUBs recognise and show selectivity for particular ubiquitin chain 
architectures and may not be able to remove the proximal ubiquitin molecule that is directly 
attached to the protein (recently reviewed in 11). Linkage selectivity can either be encoded within 
the catalytic domain, or conferred through co-operation with ubiquitin binding domains within 
DUBs or their interaction partners. 
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 Here, we will focus on recent advances in understanding the physiological functions of 
DUBs, emphasising examples where selectivity towards particular ubiquitin chain architectures 
connects with defined cellular roles, e.g. in DNA repair, cell cycle and innate immune signaling 
pathways. We also discuss how selective DUBs can provide analytical tools for investigation of 
ubiquitin chain architecture and conclude by highlighting recent advances spurring their 
development as therapeutic targets. 
 
DUB families 
 Six of the seven families of DUBs (USPs, UCHs, OTUs, MJDs, MINDYs, ZUP1) are 
classified as cysteine proteases, whilst the JAMM/MPN family are zinc-dependent 
metalloproteases. With the exception of the MJDs each family is conserved from yeast to humans 
(Figure 1). Eleven of ninety-nine family members are considered to be pseudoenzymes, in that 
they have lost residues critical for DUB activity, but can nevertheless perform vital functions 12. 
This is particularly common in the twelve member JAMM family, which contains five 
pseudoDUBs.  The phylogenetic relationships and domain structures of the five longest 
established families (USP, OTU, Josephin (MJD) , UCH and JAMM) have been covered 
extensively elsewhere 9,10. Two new families of DUBs have recently been discovered. The MINDY 
family has two members in S. cerevisiae, and is expanded to five in humans, including one 
pseudoDUB 13. Little is known about cellular function of this family, but each member tested to 
date shows specificity for Lys48 linked ubiquitin chains, strongly indicating roles in protein 
homeostasis 14. The human genome contains one representative of the ZUP1 family, whose 
specificity for Lys63-linked chains is conferred by multiple ubiquitin binding domains and which 
has been linked to genome maintenance pathways 15-18. Figure 1 provides an updated overview of 




 DUBs are proteases which cleave peptide or isopeptide bonds between conjoined 
ubiquitin molecules or between ubiquitin and a modified protein. The complexity of ubiquitin chain 
architectures dictates a wide variety of distinct DUB activities and preferences (Table 1)11. 
Adjacent ubiquitin molecules, within a chain, are not equivalent: throughout, we will refer to the 
“distal” ubiquitin, as that which presents its C-terminal glycine to the DUB active site and which 
links to a “proximal” moiety via the scissile bond. Aside from discriminating chain linkage type, 
DUBs may choose between processing from the distal end, gradually chewing down the chain 
(exo-DUB activity), or cleaving within chains (endo-DUB activity). Chain length provides another 
variable, with some DUBs preferring longer chain types (e.g. MINDY, OTUD2 and ATXN3) 13,19,20. 
Others will specialise in the cleavage of monoubiquitin from specific protein substrates (e.g. 
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histone directed DUBs, see below) or clipping off an intact ubiquitin chain (en-bloc cleavage, e.g. 
proteasomal DUBs, see below). Three enzymes containing DUB catalytic domains were later 
shown to specifically target ubiquitin like molecules; USPL1 is a SUMO protease 21,  USP18 is an 
ISG15 specific protease 22 and the COP9 signalosome component CSN5 targets NEDD8 23. The 
members of the OTU family display diverse chain preferences and their study unveiled many 
principles of DUB chain linkage specificity 11,20,24. In contrast, systematic studies of USP family 
members showed orders of magnitude differences in catalytic turnover but only modest ubiquitin 
chain preferences 25,26. However, a sub-set of USP enzymes, including USP30 and CYLD show 
marked chain preferences that are encoded in their catalytic domains (Table 1) 27-29. Despite a 
wealth of structural information (reviewed in 11), prediction of linkage or substrate specificity 
remains challenging and needs to be determined biochemically. 
 
Counting and mapping DUBs 
 To understand the impact of individual DUBs on cellular processes, both individual protein 
copy numbers and location are important considerations. Mass spectrometry derived data sets 
can provide global protein copy number estimates. For DUBs, the estimated range covers several 
orders of magnitude from low hundreds (limit of detection) to hundreds of thousands per cell for 
the most abundant enzymes 2. Available data suggest that high copy number DUBs perform 
broad “housekeeping” functions (e.g. proteasomal DUBs) whilst the rarer forms have more 
specialist roles. Several linkage specific DUBs are highly represented including OTUB1 (Lys48), 
OTUD7B (Cezanne; Lys11) and OTULIN (Met1). Some of these (e.g. OTULIN) may globally 
suppress the accumulation of ubiquitin chains bearing these linkages 30. In practical terms, this 
would effectively suppress the background noise, against which a specific or localised signal can 
emerge. 
 Multiple approaches have been used to determine the sub-cellular distribution of DUBs 
(Figure 2). Systematic mapping of GFP-tagged DUBs, using fluorescence microscopy in 
mammalian cells, has allowed the broad classification of DUBs with predominantly cytosolic or 
nuclear localisation 31. A sub-set of enzymes show specific association with a variety of defined 
structures including nucleoli (USP39), microtubules (USP21) and the plasma membrane (USP6). 
Two DUBs, USP19 and USP30 possess trans-membrane domains and show distinct localisations 
to the endoplasmic reticulum (ER) or mitochondria and peroxisomes, respectively 32,33. This 
system-wide approach has been extended to screen for DUBs which translocate following a 
specific cellular perturbation (e.g. DNA damage 34). An orthologous approach is to combine sub-
cellular organelle fractionation with quantitative mass spectrometry, which has the further 
advantage of providing an estimate of the protein copy number associated with each organelle 35. 
Detailed studies of individual DUBs have also revealed locations which were not captured in 
global screens. For example several additional DUBs have recently been added to the 
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complement of centrosomal DUBs (USP21, USP33, USP9X) 36-39. Figure 3 provides a synthesis of 
currently available data. Numerous DUBs are produced as multiple splice variants, which localise 
to different compartments and may turnover at different rates. Interesting examples include, 
USP19 which localises to the Endoplasmic Reticulum (ER) or cytosol depending on the presence 
of a trans-membrane domain 32,40, USP33 which localises to the ER and Golgi 41 and USP35 for 
which one form localises to the ER and to lipid droplets and others to the cytosol 42. A short form 
of USP35 has also been linked to mitochondria, but this variant lacks an intact catalytic domain 43. 
  
Cellular functions of DUBs 
 
 The essential DUBs. 
 The introduction of whole genome based CRISPR/Cas9 screens for viability across large 
numbers of cell lines has generated an overview of those DUBs that are required across multiple 
cell types i.e. represent core fitness genes 44,45. The collated results of major studies are presented 
in Table S1. The essential DUBs are widely expressed in high copy numbers 2. Three pairs of 
proteins stand out, each of which are embedded within ancient multi-molecular complexes 
(Figure 4). Two pseudo-DUBs from different families, USP39 and PRPF8 are components of the 
spliceosome complex involved in pre-mRNA splicing at the nucleolus. PRPF8, a large protein, is 
remarkable in containing no less than 4 pseudoenzyme domains showing homology to restriction 
endonuclease, reverse transcriptase and RNAaseH in addition to an inactive JAMM domain. The 
JAMM family members COPS5 and COPS6, active and inactive respectively (also called an 
MPN+:MPN unit), cooperate within the core of the eight sub-unit COP9 signalosome, to remove 
the ubiquitin like molecule NEDD8 from Cullins and thereby inactivate Cullin-RING E3 ligases 
(CRLs) 23. An essential DUB module comprising a further MPN+:MPN combination, PSMD14 and 
PSMD7 (Rpn11 and Rpn8 in yeast), is involved in substrate processing by the proteasome (see 
next section and Figure 4) 46. 
 USP5 is the most abundant of a set of DUBs (including USP3, USP13, USP16, USP22, 
USP33, USP44, USP45, USP49) that bear zinc finger ubiquitin binding domains (ZnF-UBP), which 
in some (e.g. USP3, USP5, USP16) but not all cases (e.g. USP13, USP22, USP33) has been 
shown to recognise the carboxyl-terminal Gly-Gly motif of unattached ubiquitin 47,48. This confers 
the capacity to specifically recognise free ubiquitin chains, which may be derived from newly 
synthesised linear ubiquitin or from chains that have been removed from substrates en bloc. 
Thus, USP5 is a core fitness protein by virtue of suppressing the accumulation of unattached 
ubiquitin chains and maintaining levels of monoubiquitin, the essential currency of the ubiquitin 
economy. Its activity against free chains has also recently been proposed to promote the 
disassembly of heat induced stress granules 49. USP36 is a  prominent nucleolar DUB and most 
likely contributes to cell viability by governing the stability of RNA polymerase 1 and consequent 
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ribosome biogenesis 50. Some of the other DUBs that are also widely required for cell viability 
(USP7, USP8 collated in Table S1) are mentioned elsewhere in this article, others are less well 
studied, such as the SUMO specific USPL1 21,51. 
 
Proteasomal DUBs and en bloc ubiquitin chain cleavage 
 Ubiquitin was first linked to protein degradation through elucidation of its role as a 
proteasome targeting signal 52. The 26S proteasome consists of a barrel shaped core particle 
(20S) capped at one or both ends by a 19S regulatory particle. The 19S regulatory particle 
provides a binding platform for ubiquitin and co-ordinates entry into the 20S core particle where 
proteins are degraded. It is now clear that multiple types of ubiquitin chains, including branched 
architectures, provide efficient proteasomal targeting signals 53-56. Three catalytically active DUBs 
from distinct families, USP14, UCHL5 and PSMD14, are associated with the lid of the 19S 
regulatory particle and co-ordinate essential proteasomal substrate pre-processing 57.  
 For protein degradation to occur, a substrate must be unfolded to thread into the catalytic 
chamber of the 20S particle. Attached ubiquitin provides a barrier to translocation and must be 
removed. The JAMM family member, PSMD14, sits directly on top of this entry portal that is 
comprised of a hexameric ring of AAA-ATPases  58,59. Purified proteasomes lacking this DUB 
activity are deficient in protein degradation. A current model maintains that for substrates 
committed to entering the catalytic chamber, attached ubiquitin chains are mechanically drawn to 
the entry port by concerted ATPase activity of 19S associated AAA-ATPase proteins and thereby 
encounter the catalytic site of PSMD14, followed by hydrolysis of the isopeptide bond at the 
substrate lysine 46,60-62. Although PSMD14 itself neither binds nor hydrolyses ATP, its DUB activity 
is indirectly ATP-dependent by virtue of this coupling 63,64. 
 PSMD14 forms a dimer with the MPN family member pseudo-DUB, PSMD7. Isolated 
PSMD14/PSMD7 heterodimers show little ubiquitin linkage specificity in vitro 60. However once 
incorporated into the regulatory particle, steric inhibition by components of the entry portal 
precludes di-ubiquitin spanning the catalytic centre. This ensures that ubiquitin chains are 
removed en bloc as only the isopeptide bond between the substrate lysine and the C-terminus of 
the first ubiquitin can be hydrolysed 64. The active site organisation of PSMD14 is similar to the 
endosomal DUBs AMSH and AMSH-LP (see also below). However, these proteins have stringent 
specificity for Lys63 ubiquitin chains, conferred by an insertion loop in the catalytic domain (Ins-2 
loop) that enables binding to the proximal ubiquitin 65. The equivalent loop in PSMD14/Rpn11 
serves to anchor the protein within the proteasome 46,60. 
 When ubiquitylated proteins first bind to the proteasome they are not yet committed to 
degradation. That step is believed to require presentation of a constitutively or transiently 
unfolded region to the ATPase machinery 57. In distinction to PSMD14, USP14 and UCHL5  (also 
known as UCH37) are not integral components of the proteasome. They bind to lid components 
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PSMD11 (Rpn6 in yeast) and RPN13 respectively, which leads to their activation 66-69. Neither DUB 
represents an essential gene, with UCHL5 completely lacking in S. cerevisiae. Rather than 
coupling to degradation, the combined activities of USP14 and UCHL5 may offer a reprieve from 
degradation by releasing proteins from the proteasome before the AAA-ATPase motor has 
engaged. 
 USP14 may also play a positive role in protein degradation by pre-processesing certain 
proteasome substrates in an interesting way, which has been elucidated using Cyclin B as a 
model. The APC/Cyclosome (APC/C) ubiquitylates Cyclin B with multiple chain types spread 
across the disordered N-terminus of the protein, to provide an efficient proteasomal degradation 
signal 68,70. Deubiquitylation of Cyclin B by proteasome associated USP14 is rapid and ATP-
independent. Reducing the number of ubiquitylation sites on Cyclin B revealed that USP14 shows 
a marked specificity for a substrate with multiple chains attached, irrespective of tested chain 
linkage types. When faced with Cyclin B bearing multiple tetraubiquitin chains, two surprising 
results were found. The cleavage reaction yields intact tetraubiquitin chains i.e. cleavage occurs 
en bloc, as discussed above for PSMD14. Secondly, the reaction yields a substrate with a single 
residual tetraubiquitin chain attached 68. Therefore, in the case of a multi-ubiquitylated substrate 
USP14 and PSMD14 appear to function in series. USP14 strips off supernumerary ubiquitin 
chains in order to relieve the burden on PSMD14, which must compete effectively with protein 
unfolding activities. 
 Substrates of UCH family proteins are restricted according to leaving group size by a 
flexible active site cross-over loop (ACL), characteristic of this family 71. When Ub-AMC, a 
fluorescent substrate presenting a small leaving group, is provided, UCHL5 is the most active 
proteasomal DUB 72,73. However, it shows poor activity towards ubiquitin-protein conjugates and 
homotypic ubiquitin chains of any linkage type 54,68. 19S Regulatory particle associated UCHL5 
can trim chains from the distal end irrespective of linkage type, but the slow time scale brings into 
question the physiological relevance of these findings 74. It has been proposed that specific 
substrates may be sufficiently flexible to loop through the ACL 69. If so, this would again result in 
en bloc ubiquitin chain removal. 
        The identity of physiologically relevant substrates of UCHL5 and other UCH enzymes 
remains an open question. Interestingly, UCHL5 moonlights as part of the chromatin remodeling 
complex INO80 that functions in transcription and DNA repair (see also below for discussion of 
DUBs in DNA repair) 34,75. In fact, CRISPR/Cas9 cell viability screens across multiple cell lines 
reveal that sensitivity of particular cell lines to loss of UCHL5, correlates with the loss of other 
components of this complex 76. Structural studies have uncovered a role for UCHL5 interaction 
with DEUBAD domains in the regulation of its catalytic activity and that of a related family 
member, BAP1 67,69,77,78. In the case of UCHL5, its respective interactions with the DEUBAD 
domains in RPN13 and the INO80 sub-unit NFRKB, have opposite effects 77. RPN13 DEUBAD 
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activates UCHL5 whilst the NFRKB DEUBAD domain blocks ubiquitin binding and thereby acts as 
a DUB inhibitor 67,69. 
 
Nuclear DUBs act on multiple chain types to regulate chromatin and DNA repair. 
  In a fluorescence screen of 66 GFP-tagged DUBs, 12 were found to be exclusively nuclear 
and a further 16 exclusively cytoplasmic in asynchronous HeLa cells 31. Thus, a large fraction of 
DUBs experience the nuclear environment, where they can influence genome surveillance and 
repair pathways, epigenetics/chromatin organisation and transcription.  
 In HEK293 cells it is estimated that around 60% of conjugated ubiquitin is in the form of 
monoubiquitin, about half of which is associated with the histone enriched fraction 8. About 5-
15% of histone H2A is mono-ubiquitylated, principally at Lys119, making H2A the most abundant 
ubiquitylated protein in the cell. Ubiquitin is therefore a major post-translational component of the 
histone landscape, that influences chromatin structure and function, together with methylation 
and acetylation. Early pulse-chase studies showed that this modification on H2A has an average 
half-life of ~90 minutes in HeLa cells, inferring histone directed DUB activity 79. As described 
below, at least 6 DUBs have now been linked to histone deubiquitylation  (Figure 5).  
 MYSM1 is the only mammalian DUB that has clear chromatin binding domains, 
incorporating both SWIRM (Swi3p, Rsc8p and Moira) and SANT (SWI-SNF, ADAN-CoR, 
TFIIIB)/Myb domains. Accordingly, it is one of several DUBs linked with histone deubiquitylation 
alongside BAP1, USP3, USP16 and USP22 80-83. The three USPs possess a ZnF-UBP domain, N-
terminal to their catalytic domain. In USP3 and USP16, this domain recognises the free C-
terminus of ubiquitin (see above) and can act as a free ubiquitin sensor in the nucleus, but it may 
also recognise as yet unidentified chromatin components or associated factors 48. For example 
histone H4 has a C-terminal diGly motif in common with ubiquitin.  
 USP22 is a component of the Spt-Ada-Gcn5-acetyltranserase (SAGA) complex 
responsible for deubiquitylation of H2B-Ub (see below). In this case its ZnF-UBP domain does not 
recognise free ubiquitin, but is instead used to make interactions with other SAGA complex 
components that are required for its activation 48,84. The UCH family member and tumour 
suppressor, BAP1, is commonly mutated in certain cancer types 85. For deubiquitylation of Ub-
H2A, it requires activation by interaction with ASXL, recalling the activation of UCHL5 by RPN13 
described above 77,78,86. BAP1 and ASXL proteins together form the Polycomb repressive 
deubiquitinase (PR-DUB) complex that sits on Polycomb group target genes and maintains 
silencing of a particular sub-set of genes 83. The complex is specific for mono-deubiquitylation at 
Lys119 and cannot remove DNA damage-dependent ubiquitylation of H2A at Lys13 or 15 (see 
below)78. 
 The study of DUBs in DNA damage repair pathways has been particularly intensive 87. 
The first shRNA screen across the DUB family identified USP1 as the DUB that removes 
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monoubiquitin from Fanconi anaemia group D2 protein (FANCD2), a key protein involved in the 
Fanconi Anaemia DNA cross-link repair pathway 88. USP1 similarly deubiquitylates the DNA 
processivity factor PCNA, in order to curb the error prone translesion synthesis repair pathway 89. 
Global proteomics studies have revealed thousands of ubiquitylation events as part of the DNA 
damage response to UV and ionising radiation, coupled to an enigmatic bulk increase in Lys6 and 
Lys33 chains 90. Accordingly, a multi-parametric screen of DNA damage signatures, alongside 
numerous other studies has associated many DUBs with this response 34 (Figure 5).  
 Ionising radiation induced DNA double strand breaks (DSBs) lead to recruitment of an 
RNF20/RNF40 E3 ligase heterodimer at the site of damage, resulting in monoubiquitylation of 
H2B at Lys120. This is believed to initiate chromatin opening, which then allows access for repair 
factors 91-93. Subsequent deubiquitylation at this site has been attributed to USP22, acting within 
the SAGA complex 91. Its activity is required for  optimal phosphorylation of Histone H2AX 
(denoted γ-H2AX) 94. Lys63-linked chains are both abundant at DNA damage sites and required 
for double strand break repair 95. The E3 ligase RNF8 is recruited to phosphorylated γ-H2AX, 
where it can generate Lys63 chains on linker histone H1 or on the RNF168 interacting protein, 
L3MBTL2 (lethal(3) malignant brain tumour like protein 2) 96,97. Lys63 chains at repair sites serve to 
recruit a second E3, RNF168, which promotes mono-ubiquitylation of H2A at Lys13/15 and 
further Lys63 polyubiquitylation 98. Following DNA damage, the normally short-lived RNF168 is 
itself stabilised through the activity of USP34, which is recruited to damage sites 99. The Lys13/15 
monoubiquitylation signal on H2A partially determines the recruitment of 53BP1, a critical step in 
initiation of the non-homologous end joining DSB repair (NHEJ) pathway 100. USP51 has been 
shown to specifically reverse this signal and thereby regulate DNA damage repair 101. Lys63-linked 
chains also mediate recruitment of the BRCA1-A complex (see below). RNF8 further co-operates 
with UBE2S to generate Lys11 chains on H2A. This promotes transcriptional silencing associated 
with DNA repair, and is antagonised by the Lys11 specific DUB, Cezanne 102. Although it is 
nominally a Lys48 specific DUB, the highly abundant OTUB1 limits Lys63 chains in the DSB repair 
pathway by binding to and inhibiting transfer from the ubiquitin-charged E2 enzyme Ubc13 103-105. 
 The JAMM family member, BRCC36, functions within the BRCA1-A complex consisting of 
RAP80, BRCC45, MERIT40 and ABRAXAS1 (FAM175A), to which BRCA1 is associated in a 
phosphorylation-dependent manner. ABRAXAS1 contains a MPN like domain that is not itself 
catalytically active. The MPN+:MPN related heterodimer of BRCC36 and ABRAXAS1 is likely to 
constitute the minimal active enzymatic unit, recalling other such couples already described 
above (see also Figure 4) 12. BRCA1-A is recruited to sites of DSB sites by RAP80 binding to 
Lys63-linked chains. Chain selectivity of this complex is stringent towards Lys63 and hence 
provides exquisite feedback control to limit the RNF8 ubiquitin signal. BRCC36, BRCC45, Merit40 
proteins also form a cytosolic complex with an ABRAXAS1 paralogue, ABRAXAS2/KIAA0157 and 
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adaptor protein SHMT2, collectively known as the BRISC complex (BRCC36 isopeptide complex), 
which has been linked to stabilisation of type 1 interferon receptor 106.  
 BRCA1 itself, promotes DNA end resection to produce the ssDNA necessary for homology 
directed repair (HDR). Its N-terminus associates with BARD1 to generate an active E3 ligase that 
ubiquitylates H2A at Lys 125/127/129 and promotes resectioning, which can be reversed by 
USP48 107-109. It also interacts with PALB2 to recruit additional repair factors, BRCA2 and RAD51, 
to DSB sites. Of note, HDR is only active in cells in the S and G2 phases of the cell cycle, due to 
the requirement for the homologous DNA template. Accordingly, in G1 cells, repair factor 
recruitment is suppressed by ubiquitylation of PALB2 that can be counteracted by USP11 in a 
cell-cycle dependent manner 110.  
 The recently discovered ZUP1 DUB, which exhibits Lys63 specificity, interacts with the 
replication protein A (RPA) complex, which plays a critical role in the HDR and replication stress 
pathways by demarcating single strand DNA regions that are generated 15-18. Available data have 
not been able to functionally link ZUP1 to DSB repair pathways. However, ZUP1 depletion in cells 
with elevated ssDNA resulting from replication stress (e.g. hydroxyurea treatment) leads to 
enhanced micronuclei generation indicative of chromosome instability 15,18. 
 
DUBs  and innate immune receptor signalling (linear and Lys63 chains). 
 Many receptor initiated signaling cascades are now known to utilise the ubiquitin code. 
This concept was first established from studies of innate immunity and the central NFκB 
signaling pathway, which invoked the requirement or Lys63 linked chains 111. This pathway has 
continued to provide fresh insight, including clearly defined roles for chain-specific DUB activities. 
It is now appreciated that innate immune signaling mediated by pattern recognition (e.g.TLR4, 
NOD2) or cytokine receptors (e.g. TNFR and IL-1R) involves the assembly/disassembly of both 
Met1, and Lys63 chains on components of the receptor signaling complexes (Figure 6). 
  The activated pattern recognition receptors and cytokine receptors recruit adaptor proteins 
including Receptor Interacting Protein Kinases (RIPK1 or RIPK2), Myeloid Differentiation Primary 
Response 88 (MyD88) or Interleukin 1 Receptor Associated Kinases (IRAKs). Their modification 
with Lys63 Ub chains serves as a recruitment platform for the TAB1/TAK1 kinase complex, an 
initiator of multiple kinase cascades 112. Ubiquitylation of receptor adaptors also promotes 
recruitment of the Met1 specific E3-ligase LUBAC 113,114. This results in assembly of Met1 ubiquitin 
chains on the adaptors directly, or on existing Lys63 chains leading to branched or hybrid chains 
113,115-117. These Met1 chains mediate downstream signaling by interaction with the inhibitor of 
nuclear factor kappa-B kinase (IKK) sub-unit NEMO 118. Co-localisation of TAK1 and IKK leads to 
IKK activation. This then activates a cascade leading to ubiquitylation and degradation of inhibitor 
(IκB) proteins, which allows NF‐κB to enter the nucleus and turn on target genes involved in 
immune and inflammatory responses 112. 
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 OTULIN, a stringent Met1 linkage specific DUB, binds to the PUB domain of the LUBAC 
component HOIP 117,119-122. CYLD, belonging to the USP family and specific for Lys63 and Met1 
ubiquitin chains 123,124, can also indirectly bind to the same domain on HOIP through an adaptor 
protein, SPATA2 125-128. Both DUBs can restrict NFκB signaling, but only OTULIN controls the 
accumulation of linear ubiquitin on LUBAC components and thereby maintains their protein 
stability 30,117,119,129-135. In addition, depletion of OTULIN, but not CYLD, leads to a dramatic increase 
of steady-state Met1 chain levels in cells 30,120,134,136 suggesting that OTULIN is essential for 
globally restricting Met1 chain accumulation, and implying a more specialised role for CYLD. 
 The binding of OTULIN and CYLD to LUBAC is mutually exclusive 125,133, suggesting that 
they regulate distinct aspects of signalling. Indeed, OTULIN is not stably associated with the 
NOD2 or TNFR1 complexes 133, although its recruitment to TNFR1 has been observed by mass 
spectrometry 128. In contrast, SPATA2-CYLD is stably recruited to both NOD2 and TNFR1 via 
HOIP 133. There is evidence that OTULIN limits Met1 chain accumulation on receptor-associated 
adaptors associated with TNFR1 and NOD2 receptors; absence of OTULIN leads to enhanced 
ubiquitylation of adaptors without changing the overall banding pattern of ubiquitylated forms as 
judged by Western blotting 117,119,134. In contrast, depletion of CYLD leads to the accumulation of 
higher molecular weight forms 134, consistent with CYLD being the major regulator of the length of 
Met1 and Lys63 chains at these receptor complexes 133. 
 OTULIN and CYLD are directly linked with human pathologies. CYLD truncations cause 
cylindromatosis characterised by the formation of benign tumours on the skin of the head and 
neck 137. Mutations in OTULIN that ablate or severely reduce activity, cause OTULIN-Related 
Autoinflammatory Syndrome (ORAS), also known as Otulipenia, which is  characterised by 
neonatal onset fevers, skin rashes, diarrhoea, arthritis, and general failure to thrive 30,138. Elements 
of both conditions have been recapitulated in mouse models. CYLD deficiency leads to 
disturbances in lymphocyte development, proliferation, and responsiveness, leading to mild 
inflammation and susceptibility to carcinogen-induced tumour formation 139-144. In contrast, mice 
expressing two different point mutant alleles of OTULIN, that encode a catalytically compromised 
protein, display embryonic lethality around E12.5-E14, which is thought to be caused by defective 
Wnt signaling 120. Conditional or cell type-specific OTULIN deletion causes severe, systemic 
inflammatory phenotypes associated with increased signalling and cytokine release from 
macrophages 30. A further knock-in mouse model expressing a catalytically inactive form of 
OTULIN (C129A) 145, dies during embryogenesis (E10.5), due to aberrant cell death. The 
phenotype resembles both germ line mutation of OTULIN and loss of LUBAC components, 
confirming LUBAC deubiquitylation as a significant physiological function of OTULIN. 
Furthermore, it suggests that cell death may contribute to systemic inflammation in mice and 
humans with OTULIN defects 30,120,138,145-147. The C129A knock-in mutation converts OTULIN into a 
high affinity ubiquitin binding domain, which binds and protects Met1-linked chains 117,119,148. In 
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ORAS/Otulipenia, decreased stability of mutant OTULIN leads to reduced protein levels. These 
two settings may respectively block and enable, compensatory CYLD recruitment to LUBAC, 
which could account for the different severity of phenotypes. 
 The OTU family DUB, A20 (TNFAIP3), is induced by NFκB following activation of pattern 
recognition and cytokine receptors 149,150. It possesses distinct binding domains for both Lys63- 
and Met1 chains 151, yet strongly favours cleavage of Lys48 linkages in vitro. However, in cells it 
can become phosphorylated, which further stimulates Lys48 activity and unleashes otherwise 
latent Lys63 directed activity 20,124,152,153. In distinction to CYLD, it is equally active towards 
branched Lys48-Lys63 chains, which have also been linked to the NFκB pathway 154. Mouse 
models expressing a catalytic site mutation of  Cys103 to Ala 153,155,156, do not fully replicate the 
phenotype of A20 loss 157. Consistent with this observation, is the finding that A20 is unable to 
cleave Met1-linked ubiquitin chains 20,26, yet regulates Met1 signalling. Recruitment of A20 to 
immune receptor signaling complexes suppresses NF-κB signaling in a catalytically independent 
manner. The primary effect of A20 is to proposed to reflect binding and sequestration of linear 
ubiquitin chains via its ZnF7 domain 133.  
 OTUD4 is nominally a Lys48 chain-linkage specific DUB that interacts with the Toll Like 
receptor interacting protein MyD88. However in cellular extracts OTUD4 shows selectivity for 
Lys63 linkages. Accordingly, OTUD4 opposes Lys63-linked ubiquitin modification of MyD88 and 
also limits NFκB signaling. Notably, selectivity for Lys63 is conferred by OTUD4 phosphorylation 
158. Such DUB “linkage switching” by post-translational modification is an interesting new 
concept, that might be more widely adopted. 
 
Endosomal DUBs 
 Activated receptor tyrosine kinases, such as EGF Receptor (EGFR), become ubiquitylated 
and undergo endocytosis. Upon reaching early/sorting endosomes, ubiquitylation is used to direct 
receptors towards the lysosomal pathway, using the ESCRT (EndoSomal Complex Required for 
Transport) machinery 159. Mass spectrometry analysis has shown that EGFR is ubiquitylated at 
multiple sites, with Lys63 being both the predominant chain linkage type and required for efficient 
sorting 160,161. The ESCRT-0 complex, comprising HRS/HGS and STAM, provides the first point of 
engagement of ubiquitylated receptors with the ESCRT machinery 159. The non-selective DUB, 
USP8, and the stringent Lys63 selective metalloprotease AMSH (STAMBP), compete for binding 
to STAM, recalling the competition between CYLD and OTULIN for LUBAC binding described 
above. Each DUB also binds a palette of ESCRT-III components via their respective N-terminal 
MIT domains 162. Recent findings suggest that USP8 controls the ubiquitylation state of the 
ESCRT-III component CHMP1B and may promote its assembly into a membrane associated 
ESCRT-III polymer 163. EGF stimulates CHMP1B ubiquitylation and also promotes USP8 
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recruitment to endosomes 163,164. Perhaps the  deubiquitylation of CHMP1B represents a check-
point governing the temporal and spatial assembly of the ESCRT-III polymer which promotes 
budding of EGFR laden vesicles into the lumen of the endosome/multivesicular body. A further 
key function of USP8 catalytic activity is to deubiquitylate and stabilise ESCRT-0, which is 
otherwise degraded by the proteasome 164. The robustness of this finding is supported by data 
from CRISPR/Cas9 cell viability screens which show a correlation in sensitivities between loss of 
either USP8 or the ESCRT-0 component HRS 76. 
 The Lys63 directed activity of AMSH is unable to compensate for USP8. However, AMSH 
can influence receptor fate; for example, it promotes the recycling of activated EGFR 165. It 
remains an open question whether the stringency of AMSH, or its close relative AMSHLP 
(STAMBPL), for Lys63-linked chains may reflect undiscovered roles in specific cell signaling 
pathways. Intriguingly, loss of function mutations of AMSH, either in the MIT or catalytic domain, 
lead to Microcephaly Capillary Malformation Syndrome (MIC-CAP) 166,167. Activating mutations in 
USP8 lead to Cushing’s disease that is characterised by pituitary corticotroph adenomas 168,169. 
The interplay between endosomal DUBs associated with the endo-lysosomal degradation 
pathway parallels aspects of proteasomal DUBs discussed above. Endosomal and proteasomal 
DUB activities can both reprieve proteins, but are also required to recycle ubiquitin following 
commitment towards the respective degradation pathways 170. 
 
Lys6 chains, phospho-ubiquitin and the role of DUBs in mitophagy 
     The selective autophagy of organelles or protein aggregates can be mediated by distributed 
ubiquitin chains which generate the avidity for low affinity adaptor molecules that link the 
autophagic cargo to the autophagic membrane 171. This provides an opening for DUBs to regulate 
autophagy, the third major pathway of protein degradation, in addition to the lysosomal and 
proteasomal pathways 172. The selective clearance of damaged mitochondria (mitophagy) has 
elicited much interest, particularly since the process can be driven by two Parkinsons disease 
linked genes PINK1(PARK6) and Parkin (PARK2) 173. 
 The E3 ligase Parkin preferentially, but by no means exclusively, generates Lys6-linked 
chains upon its activation at damaged mitochondria 173-175. Inhibitory auto-ubiquitylation of Parkin 
with predominantly Lys6 chains is proposed to be contained by the non-specific USP8, which 
enables Parkin recruitment to mitochondria 176. USP30 localisation is confined to mitochondria 
and peroxisomes courtesy of a trans-membrane domain and adjacent polybasic residues 33,177. It 
too, shows selectivity for Lys6 ubiquitin linkages and is suggested to restrict Parkin ubiquitylation 
of some proteins (notably TOMM20) and thereby limit mitophagy 28,29,175,178-180. Parkin activity is 
controlled by PINK1, that phophorylates ubiquitin at Ser65 the UBL domain of Parkin itself at an 
equivalent position 181-183. Parkin is recruited to mitochondria by this phospho-ubiquitin and 
creates more PINK1 substrate by further ubiquitylating mitochondrial proteins in a feed-forward 
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loop. This represents the physiological context where the role of ubiquitin phosphorylation is best 
understood, although other phosphorylation sites on ubiquitin have also been identified 184.  
 How does phosphorylation of ubiquitin influence DUB activity and selectivity?  Chains 
assembled from Ser65 phosphoubiquitin provided poor substrates for a panel of 12 DUBs, with 
few exceptions 180. In a separate study 20 isomeric dimers of phosphoubiquitin, with 
phosphorylation at Ser20, Ser57 or Ser65 were profiled against 31 DUBs, most of which were less 
able to cleave the phosphoubiquitin dimers than their unphosphorylated counterparts 185. This 
finding is particularly pronounced for Ser65 phosphorylation of ubiquitin and is accounted for by 
structural considerations 180,185. In the case of USP30, Ser65 phosphorylation impairs activity 
against Lys6 and other chain types 28,180. Structural and biochemical analysis of Lys6-linked 
ubiquitin dimer processing reveals that phosphorylation of the distal ubiquitin but not the proximal 
ubiquitin is incompatible with USP30 engagement. In fact, in a tetra-ubiquitin molecule a single 
phosphorylation of the distal ubiquitin is sufficient to hinder hydrolysis to a similar extent as the 
fully phosphorylated form. Thus, at mitochondria, PINK1-dependent phospho-capping of Lys6-
ubiquitin chains will generate a DUB-resistant mitophagy signal, preserving recruitment sites for 
Parkin and adaptor proteins that link the mitochondria to autophagosomal membranes. For this 
reason, recent models have proposed a role for USP30 upstream of PINK1, by limiting initial 
PINK1-substrate availability and setting the threshold for PINK1 dependent mitophagy 28,33,186. 
 
DUB control  of Lys11 chains and the cell cycle 
 Multiple DUBs have been linked to different stages of the cell cycle, but it is during mitosis 
that linkage selectivity appears to be most critical 187. The onset of anaphase is governed by 
activation of the E3 ubiquitin ligase complex, APC/C, which promotes the degradation of CyclinB 
and Securin. Thereafter, it targets multiple substrates until it again becomes inactive at the end of 
G1. In metazoa, APC/C teams up with UBE2C to build short chains linked by Lys11, Lys48 or 
Lys63 molecules onto substrates and then with UBE2S to extend and branch existing chains with 
Lys11 linkages 188-191. UBE2S branching activity has been shown to be required for efficient 
proteasomal degradation of various substrates 53,192. The OTU family member Cezanne is the most 
prominent Lys11 specific DUB and accumulates during mitosis 20,24,193,194. It has been shown to 
control the degradation kinetics of some (e.g Cyclin B and Securin) but not all APC/C substrates 
during mitotic progression 194. Moreover, depletion of Cezanne leads to accumulation of 
micronuclei during mitosis which can be reversed by co-depletion of UBE2S. Interestingly, 
Cezanne is amplified in >30% of breast tumours and is situated within an amplicon that lacks a 
verified oncogene 195. 
 
DUBs as analytical tools 
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 A suite of DUBs with defined chain linkage specificities provides a useful analytical tool to 
analyse ubiquitin chain architectures by parallel electrophoretic analysis of enzyme treated 
samples. In the first instance, one can use a promiscuous DUB, e.g. USP2, to show that a protein 
is indeed ubiquitylated 196. Further analysis of banding patterns, following treatment with selective 
DUBs, allows the estimation of linkage types associated with a particular protein substrate. By 
analogy with restriction digests used in molecular biology, this has been termed ubiquitin chain 
restriction (UbiCRest) analysis 197. UbiCRest analysis enables first insights into the architecture of 
heterotypic ubiquitin chains. One elegant example combined USP2 (non-specific), OTULIN (Met1-
Ub specific) and AMSHLP (Lys63 specific) to dissect the ubiquitin chain linkages associated with 
innate immune signaling components and led to the discovery of the presence of heterotypic 
chains consisting of Met1 chains built upon a Lys63 linked scaffold 116. 
  
DUBs as therapeutic targets 
   Linkage of DUBs to the stability of specific client proteins has offered a means to extend 
the druggable proteome (Table S2)198. In a nutshell, for any protein turned over in a ubiquitin 
dependent fashion, inhibition of it’s cognate DUB may lead to protein destabilisation. High value 
oncology targets linked to DUBs include MYC (USP28, USP36, USP37), NMYC (USP7), 
MDM2/p53 (USP7) and MCL-1 (USP13,USP9X) 199-203. Many small molecule DUB inhibitors have 
been reported in the literature, but until recently few of these have been specific 26. 
 The response to DNA damage is controlled by the tumour suppressor gene and 
transcription factor p53, which can promote either apoptosis or cellular senescence. The short 
half-life of p53, typically around 10 minutes, enables rapid adjustment in protein levels through 
changes to turnover kinetics. The most prominent E3-ligase associated with p53 is MDM2, whose 
own stability is governed by autoubiquitylation. Under basal conditions, USP7 binds to MDM2 
and rescues it from degradation, indirectly reducing p53 levels 204. In the last year, several 
publications have reported highly specific USP7 inhibitors that all elevate p53 levels 205-208. 
Although, USP7 inhibitors retard tumour growth in a mouse xenograft model, available evidence 
suggests that this is independent of p53 status 207,209. MDM2 is just one of many physiological 
substrates linked to USP7, which include other proteins linked to tumour growth such as PTEN, 
FOXP3 and Claspin 210-212. One inhibitor developed by Genentech from fragment screening binds 
12Å from the catalytic centre and impedes binding of the distal ubiquitin of the favoured Lys48-
linked substrates 205. The three other studies converge on small molecules with a shared core 
structure, making identical key contact sites, as revealed by high resolution crystal structures 206-
208. Interestingly, these critical contact residues are conserved in other USP family members. The 
exquisite specificity of these compounds arises from a unique USP7 configuration in its ubiquitin-
unbound form 213. In this apo-form, the catalytic triad essential for hydrolysis is misaligned and a 
cleft between structural domains is rendered compatible for compound binding about 5Å from the 
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catalytic cysteine. These studies have generated tool compounds for acute manipulation of USP7 
activity that may inform clinical positioning of candidate drug molecules.  
 Inhibition of the 19S proteasome regulatory particle DUB, PSMD14 suppresses 
proteasome activity. The development of specific PSMD14 inhibitors is at an early stage, but a 
proof of principle has been established 214. Successor compounds may offer therapeutic 
alternatives to the established inhibitors of active sites in the 20S core particle, such as 
Bortezimib, which are used to treat multiple myeloma. In contrast inhibition of another 19S 
regulatory particle DUB, USP14, enhances the degradation rate of certain proteins linked to 
neurodegeneration, such as the Alzheimer’s Disease linked Tau and Prion proteins 215-217. The 
USP14 inhibitor (IU1) occupies a similar cleft in the structure to several of the USP7 inhibitors, 
albeit with a different orientation 206-208,218.  All these compounds block access of the ubiquitin C-
terminus to the catalytic centre. Inspection of the patent literature suggests that similar 
breakthroughs have been made for further DUBs of therapeutic interest 198. The emerging picture 
suggests that the conformational plasticity of the USP catalytic domain frequently offers 
opportunities for selective inhibition. 
 
Conclusions 
 At least a third of active DUBs have now been assigned some level of specificity with 
regard to their action on ubiquitin chains or ubiquitin like modifiers. Alongside this, information on 
copy numbers and localisation, has begun to provide a composite outline of their collective 
impact on the cellular distribution of ubiquitin. We now appreciate that complex cellular processes 
such as DNA repair and innate immune signaling rely on co-ordination between different ubiquitin 
chain linkage types, that is facilitated by DUBs with cognate specificities (e.g. Met1, Lys48, 
Lys63). However, our understanding of the biology associated with some chain linkage types 
remains very limited and further levels of complexity (post-translational modification of ubiquitin, 
branched chains) are presenting new frontiers. Knowledge of specificity and discovery of new 
DUB activities have led to their adoption as analytical tools. Association of individual DUBs to key 
pathways in oncology, immunity and neurodegeneration are driving drug discovery programmes 
that have rendered the first generation of highly specific inhibitors. 
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cleavage type DUB Refs 
Lys63 AMSH, AMHLP, BRCC36, OTUD1, ZUP1, 
CYLD, pOTUD4 
65,124,219,220, 20, 
15-18, 13, 27,124, 
158 
Lys48 OTUB1, OTUD4, A20, MINDY 20,13 
Lys29/33 TRABID 221 
Lys11 Cezanne 24,193 
Lys6 USP30 28, 29,175 
Linear OTULIN, CYLD 119,120 
non-specific most USPs (e.g. USP2, USP21) 25 
en-bloc PSMD14, USP14, UCHL5? 64,68,69 
free chains USP5, USP3, USP16 47,222, 223 
histones 
(monoUb) 
MYSM1, USP3, USP16, USP22, BAP1 81,80,82,78 
NEDD8 COPS5 23 
SUMO USPL1 21 
ISG15 USP18 22 
 
  
Table 1: Summary of known ubiquitin chain linkage or other modification preferences of DUBs 
reported in the literature. The table indicates DUBs for which biochemical evidence indicates a 
significant degree of selectivity between chain architectures for the isolated enzyme or embedded 








Figure 1 - Major Roles of DUBs 
DUBs have key roles in maintaining protein homeostasis and signaling in cells by; (a) removing 
non-degradative ubiquitin (Ub) signals which may regulate protein function directly or contribute 
to the assembly of multi-protein signalling complexes; (b) rescuing proteins from either 
proteasomal or lysosomal degradation, (c) maintaining ubiquitin levels by recycling ubiquitin from 
proteins that are committed to degradation (d) and (e) post-processing following en bloc ubiquitin 
chain removal to maintain free ubiquitin levels, (f) generation of newly synthesised ubiquitin by 
releasing monomeric ubiquitin from multimeric precursor proteins encoded by four genes. UBB 
and UBC encode multiple copies of ubiquitin that are transcribed and translated as linear fusion 
proteins with a C-terminal extension of one or two amino-acids (shown in pink). UBA52 and 
UBA80 yield ubiquitin fused to the amino terminus of two ribosomal subunits, 40S ribosomal 
protein L40 (L) and 60S ribosomal protein S27a (S). Thus DUBs are also indirectly involved in 
ribosome biogenesis.  
 
Figure 2 - Phylogenetic conservation of DUBs across model organisms 
DUBs are arranged according to a bootstrapped neighbour joining phylogenetic analysis of their 
catalytic domains with the most reliable nodes (supported by bootstrap values of >50%) 
indicated by a black dot ( see 10 for further detail). The following newer members were curated 
and added manually: OTULIN, FAM105A, the MINDY family, ZUP1, ALG13. A single 
representative member of the expanded USP17 family is shown (USP17L2). DUBs annotated with 
* are predicted to be inactive based on sequence or structural considerations. Note that zebrafish 
MINDY4B is predicted to be active (personal communication, Kay Hofmann). Blue bars indicate 
human sequences, purple, green and yellow bars indicate the presence of a clearly identifiable 
orthologue in zebrafish (D. rerio), fly (D. melanogaster) or in either one of two commonly used 
yeast species (S.pombe and S.cerevisiae) respectively. In the latter case some orthologues 
cannot be directly assigned to one or the other paralogue (e.g. MINDY1/2). DUBs that have a 
discernible orthologue in yeast, are indicated in red. Note these include all the essential DUBs 
shown in Figure 4. 
 
 
Figure 3 -Sub-cellular localisation of DUBs in mammalian cells. 
DUBs which are predominantly localised to the nucleus or with clearly identifiable sub-cellular 
structures are shown. Data are derived from a systematic sub-cellular localisation screen in HeLa 
cells 31 combined with individual studies collated here to supplement this overview. pm, plasma 
membrane; mvb, multivesicular body; ee, early endosome; er, endoplasmic reticulum; go, Golgi; 
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mt, microtubules; mito, mitochondria; sg, stress granules; ld, lipid droplets; ce, centrosome; nu, 
nucleus; n, nucleolus; po, peroxisomes. 
 
Figure 4 - Essential DUBs 
Seven DUB family members show a consistently high dependency score across multiple genome 
wide CRISPR and RNAi screens, comprising data from more than 400 cell lines, meaning that 
they are required for cell viability in nearly all cell types (Table S1). (a) USP39 and JAMM family 
member PRPF8 are both catalytically inactive (Pseudo-DUBs) and cooperate in pre-mRNA 
splicing. USP39 is a component of U4/U6-U5 tri-snRNP, which is a key building block of the 
spliceosome and requires PRPF8 for its assembly.  (b) The two JAMM family members PSMD14 
(active) and PSMD7 (inactive) form a functional unit within the lid of the 19S proteasome 
regulatory particle that removes ubiquitin from proteins committed to degradation. (c) COPS5 and 
COPS6 make up another DUB-pseudoDUB pair belonging to the JAMM family, that forms the 
enzymatic core of the eight subunit multiprotein complex COP9-signalosome (CSN), which 
catalyses the removal of the Ubiquitin-like protein NEDD8 from the Cullin component of  Cullin-
Ring E3 ligases (CRL). Modification of the Cullin scaffold subunit with NEDD8 (N; known as 
neddylation) on a conserved lysine is required for CRL activation. It results in a reorientation of 
RING Box 1 (Rbx1) that facilitates ubiquitin transfer from a RING-bound E2 (not shown) onto a 
substrate recruited to the substrate receptor (R) that is linked via an adaptor (A) to the Cullin. R, 
substrate receptor; A, adaptor; Rbx, Ring box protein that recruits the E2. (d) The ZnF UBP 
domain of USP5 (also called Isopeptidase T) specifically recognises a glycine at the unconjugated 
carboxy-terminal of ubiquitin and specialises in the generation of free ubiquitin by disassembly of 
unanchored ubiquitin chains. 
 
Figure 5 - DUBs implicated in the double strand break (DSB) DNA damage response (DDR) 
(a) USP22 is a DUB component of the SAGA complex, a multi-enzyme transcription co-activator 
complex, that functions in DDR to limit H2B(Lys120) by RNF20/40 E3-ligase. This ubiquitin 
modification is proposed to promote chromatin relaxation, required for the recruitment of the 
repair machinery. 
(b) DSBs activates ATM kinase (not shown) which phosphorylates both H2AX and the DDR 
scaffold protein Mediator of DNA damage checkpoint protein 1 (MDC) leading to recruitment of 
the E3, RNF8 which together with the E2 UBC13 generates Lys63-linked ubiquitin chains on 
either L3MBTL2 or Histone H1. These Lys63-linked chains (depicted in purple) can be removed by 
BRCC36 (also known as BRCC3), which forms a functional unit with the catalytically inactive 
MPN-like ABRAXAS1 protein within the BRCA1-A complex that is recruited via the RAP80 
subunit. Their formation can also be suppressed by OTUB1 inhibition of UBC13 that is 
independent of catalytic activity. Lys63-linked chains recruit a second E3 ligase, RNF168, which 
  31 
 
in conjunction with UBCH5 mono-ubiquitylates H2A on Lys13 and Lys15. This modification that is 
opposed by USP51, recruits p53BP1 and is required for DNA repair via non-homologous end 
joining (NHEJ). 
(c) Cezanne disassembles Lys11-linked ubiquitin chains that are generated by RNF8 in 
conjunction with the E2 UBE2S on damaged chromatin (including H2A) and regulate 
transcriptional silencing. 
(d) USP48 opposes the BRCA1/BARD1 ubiquitin E3 ligase that ubiquitylates H2A at Lys 




Figure 6 - Chain specific DUBs orchestrate innate immune signalling 
Activation of innate immune signalling receptors (ie pattern recognition (e.g.TLR4, NOD2) or 
cytokine receptors (e.g. TNFR and IL-1R)) involves the assembly/disassembly of both Met1 
(linear), and Lys63-linked chains on components of the primary receptor signaling complexes. The 
linear ubiquitin specific LUBAC E3 ligase complex (HOIP, HOIL-1 and Sharpin), is responsible for 
the assembly of Met1-linked chains (blue) on adapters, or on existing Lys63-linked chains (purple) 
generating branched or hybrid Lys63-Met1chains. It also undergoes auto-ubiquitylation. Met1 
chains mediate downstream signaling by interaction with the inhibitor of nuclear factor kappa-B 
kinase (IKK) sub-unit NEMO and subsequent activation of IKK via phosphorylation by TAK1, 
which is recruited via Lys63-linked chains Two DUBs engage LUBAC via the same PUB domain 
of HOIP: OTULIN, a stringent Met1-specific OTU DUB binds to LUBAC directly, whereas the USP, 
CYLD binds via an adapter SPATA2 and is able to disassemble both Lys63 and Met1-linked 
chains. OTUD4 is an intrinsically Lys48-specific DUB which is converted into a Lys63-specific 
DUB to remove such chains from MyD88, an adapter (component) of the signalling complex (not 
shown). Likewise, A20, another member of the OTU family of DUBs acquires Lys63-linked 
ubiquitin chain processing activity upon phosphorylation. In addition, A20 encodes a series of 
zinc fingers (ZnFs) that bind and sequester Met1- or Lys63-linked ubiqutin chains. 
 
  













































































































































































































































































































































































































































































































































Supplemental Table 1: Core fitness DUBs 
DUBs that show the most consistent core-dependency across  several high quality genome wide 
CRISPR screen analysis datasets 1-5 and a combined analysis of multiple comprehensive RNAi 
screens (DEMETR2) 6. Numbers of cell lines included in each analysis are indicated in 
brackets.Table indicates the percentage of cells that show dependency based on a threshold score 
shown in italics in the column header. A high degree of dependency (>80% cell lines) is shown in 
red. For the Hart et al. dataset, we chose the recommended strict Bayes Factor threshold score of 
≥ 6. A CERES score of -1 for Broad Avana (2018Q2) 2,4 and Broad GeCKO 1 datasets is 
comparable to the median of all pan-essential genes. The DEMETER2 dependency score used by 
McFarland et al., reflects shRNA depletion values taking off-target seed effects into account, where 
a score of -1 is indicative of essentiality, based on negative and positive control gene sets used for 
scaling 6. The CS score used in the acute myeloid leukemia-cell focused screen (Wang et al., 5), is 
defined as “the average log2-fold change in abundance of all sgRNAs targeting a given gene 
between initial and final cell populations” 5. Genes shown in bold are contained within the Core 





et al.     
(17)         
BF ≥ 6 
Broad 
Avana  














GeCKO   




et al.  
(14)       
CERES      
<-1 
Wang  
et al.  
(14)        
CS <-0.5 
McFarland 




PSMD14 94 99 100 100 100 100 100 81 
COPS6 94 91 100 55 100 36 100 95 
PRPF8 88 99 100 100 100 100 100 98 
USP39 88 0 44 15 100 86 100 100 
USP5 82 61 99 3 94 100 100 54 
COPS5 82 76 100 0 15 7 93 91 
USPL1 82 15 96 91 100 0 50 59 
EIF3H 71 13 93 3 85 0 36 68 
PSMD7 65 100 100 100 100 14 100 99 
USP36 65 58 100 0 58 0 79 1 
BAP1 59 1 56 3 82 0 93 5 
USP7 53 9 61 36 94 0 79 24 
USP37 53 0 53 0 61 0 86 1 
USP8 47 6 87 0 15 0 79 21 
EIF3F 47 7 94 0 76 0 36 95 
         
High >80%         
Low 50-80%         
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DUBs mutated in disease 
 Disease setting Disease association Genetic alterations References 
BAP1 Cancer Renal cell carcinoma, 
Uveal Melanoma, 
Mesothelioma 
Loss of function 1-3 
CYLD Cancer,  
Innate immune signalling 
Cylindromatosis Loss of function 4 
OTULIN Innate Immune signalling 
Inflammation 
ORAS Loss of function 5, 6 
USP8 Adenomas, Cancer Cushing’s Disease Gain of function 7 
USP48 Adenomas, Cancer Cushing’s Disease Gain of function 8 
STAMBP 
(AMSH) 
Developmental disease Microcephaly-capillary 
malformation 
Loss of function 9 
     
 Indirect extension of druggable proteome through DUB targeting 
 Disease setting Disease application Indirect targets  





USP7 Cancer neuroblastoma, 
immunotherapy 
Regulates MDM2/p53, 
NMYC, FOXP3 levels 
11, 12 






USP13   Reported to stabilise the 
anti-apoptotic protein 
MCL1 and determine 
sensitivity to BH3 mimetics 
15 
USP28 Cancer MYC driven tumours FBW7 clients 
(MYC, Jun etc) 
16-18 
PSMD14 Cancer  Alternative to established 
proteasome inhibitors 
Positive regulator of  
proteasome activity 
19 
USP14 Neurodegeneration Alzheimers Disease Limits proteasomal 
degradation 
20-23 
USP30 Neurodegeneration Parkinson’s disease Suppresses Mitophagy 24-27 
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